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Abstract 
 
Background: Worldwide sugar consumption has tripled during the last fifty years. High sugar intake is associated with 
weight gain, increased incidence of diabetes and has been linked with increased cardiovascular mortality. Reducing the 
health impact of dietary sugar and poor quality carbohydrate intake is a public health priority. IminoNorm®, a proprietary 
mulberry leaf extract (ME) may reduce blood glucose responses following dietary sugar and carbohydrate intake by 
reducing absorption of glucose from the gut. Previous research has shown that ME can reduce blood glucose and improve 
insulin responses in healthy subjects and also in subjects with raised fasting blood glucose levels. Mulberry leaf has an 
excellent safety profile. This pilot study will test a novel safe water soluble product in normoglycaemic adults in the UK 
to determine if it can reduce glucose absorption without increasing plasma insulin concentration.  
 
Methods/Design: The trial will be a double blind, individually randomised, four-arm single dose crossover design to test 
the effect of three doses of ME in order to determine efficacy, dose response relationship and gastrointestinal side effects 
with respect to placebo. A total of 40 subjects will participate in this study and attend for four visits receiving each of the 
four interventions in random order.  
 
Discussion: We aim to test the evidence that mulberry leaf extract can reduce blood glucose without a disproportionate 
increase in blood insulin responses in healthy individuals in a high-quality research study based in the UK. It is hoped that 
this will lead to further randomised controlled trials and an effective dietary supplement to lower blood glucose 
concentrations.   
 
Trial Registration: ISRCTN: ISRCTN 14597438 (21/04/2015) 
         
Keywords: Mulberry, Glycaemic Response, Insulinaemic Response 
 
Background 
Excess calorie intake including those from sugar can make a significant contribution to becoming overweight [1, 2] and 
thus increase the risk of developing Type 2 diabetes mellitus (T2DM) [3, 4]. In 2013 a large long-term European study 
investigating the effect of diet on health [5] found an association between the amount of sugary soft drinks people had and 
their risk of Type 2 diabetes. In this study weight gain had a large effect on diabetes risk and sugary drinks had a small 
effect on diabetes risk even after Body Mass Index (BMI) was corrected for.  The global rise in T2DM is linked to the 
metabolic syndrome (dyslipidemia, hypertension, insulin resistance), and obesity is thought to be one of the greatest risk 
factors for metabolic syndrome and T2DM [6].  Dietary sugars and carbohydrates play a significant role as calories from 
these foods promote fat storage and hunger [7].  A recently completed review of nutrition and its impact on T2DM 
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concluded that dietary restriction of carbohydrate intake is the single most effective approach to manage T2DM [8].  It is 
estimated that more than 1 in 17 people in the UK have diabetes (diagnosed or undiagnosed) [9] and thus reducing the 
health impact of dietary sugar and poor quality carbohydrate intake is a public health priority. Herbal agents could be 
quite effective in the management of carbohydrates in the normal diet and in reducing post-prandial blood glucose [11]. 
Mulberry (Morus alba) leaves have been used in traditional Chinese medicine (TCM) for several millennia and its use was 
first recorded in around 500AD in the Divine Husbandman’s Classic of the Materia Medica [10].  It has also been used for 
more than 750 years in Japan as an infusion tea [11].  It is used by some human communities for food purposes and in 
several Asian countries as a herbal tea.  Reports have shown that the leaves are nutritious and non-toxic [12].  The 
Chinese Ministry of Health and the Taiwanese Bureau of Food Safety recognise Morus alba leaves as both a food and a 
medicine [13]. Mulberry leaf extracts (ME) have a long history of safe use globally for normalizing post-prandial blood 
glucose, and it is thought that iminosugars such as 1-deoxynojirimycin (DNJ), a reversible, competitive natural α-
glucosidase inhibitor, are the main active components responsible for the activities [11].  
ME can significantly reduce the peak blood glucose levels and the insulin response levels (Kimura, et al., 2007; Mudra et 
al., 2007), providing protection to blood glucose metabolic function of healthy and hyperglycemic subjects [14, 15]. ME 
can reduce oxidative stress, glucose fluctuations during postprandial periods and more generally, glucose swings 
triggering effects on oxidative stress. By reducing oxidative stress, ME has the potential to slow down the process of 
prediabetes to diabetes and diabetes to developing complications [16, 17]. Long-term administration of ME produced a 
dose-dependent decrease in body weight and hepatic lipid accumulation [17], stimulated skeletal muscle 5'-AMP-
activated protein kinase activity acutely without changing the intracellular energy status [18], suppressed the elevation of 
postprandial blood glucose and cholesterol in humans [14] and exhibited potential hypoglycemic and hypolipidemic 
effects in diabetic patients [19]. Therefore, ME may help reduce blood glucose peaks caused by the ingestion sugary 
or carbohydrate rich foods and drinks. Mulberry tea has been shown to suppress the postprandial rise of blood glucose 
levels after 90 minutes of its consumption in T2DM subjects [20].        
The aim of this study is to determine the effect of three doses of a proprietary water extract of mulberry leaves 
standardized to contain 5% DNJ (IminoNorm®) versus placebo on blood glucose and insulin responses when co-
administered with 50g maltodextrin in normoglycaemic healthy adults. We also aim to determine the gastrointestinal 
tolerability of the mulberry extract using both normal (250mg IminoNorm® containing 12.5mg DNJ), half (125mg 
IminoNorm® containing 6.75mg DNJ), and double (500mg IminoNorm® containing 25mg DNJ) the normal dose. 
Maltodextrin is a dietary starch with a high glycaemic index, is commonly added to many foods and beverages and has 
been used as a test carbohydrate in similar studies [21]. We hypothesise that ME will reduce glucose excursions without 
causing a disproportionate increase in insulin release and thus its ingestion may confer protection against the development 
of diabetes, although further trials would be required to determine its long-term efficacy.  
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Methods / Design 
Objectives 
The primary objective is to determine the effect of three doses of mulberry-extract (IminoNorm®) versus placebo on 
blood glucose and insulin responses when co-administered with 50g maltodextrin in normoglycaemic healthy adults. We 
also aim to determine the gastrointestinal tolerability of the mulberry extract using both normal (250mg IminoNorm® 
capsule containing 12.5mg 1-deoxynojirimycin), half (125mg IminoNorm® containing 6.75mg DNJ), and double (500mg 
IminoNorm® containing 25mg DNJ) the normal dose. The ME (IminoNorm®) is provided by Phynova Group Ltd, UK.  
Hypothesis 
Our primary hypothesis is that an appropriate dose of mulberry extract co-administered with oral maltodextrin will reduce 
the incremental area under the curve for plasma glucose concentration over 120 minutes in normoglycaemic adults in a 
dose-dependent manner when compared to co-administration with placebo. Our secondary hypothesis is that mulberry 
extract co-administered with oral maltodextrin will not disproportionately increase the incremental area under the curve 
for plasma insulin concentration over 120 minutes in normoglycaemic adults compared to co-administration with placebo. 
Study Design 
A double-blind, randomised, repeat measure, crossover design trial will be used to study the glycaemic response (GR) and 
insulinaemic response (IR) to three products: one reference product and three test products. Participants will act as their 
own controls, i.e. each participant will test all four products.  The trial will be conducted by the Functional Food Centre at 
Oxford Brookes University. Ethical approval for the study has been obtained from the University Research Ethics 
Committee (UREC) of Oxford Brookes University, Faculty of Health and Life Sciences, Headington Campus, Gipsy 
Lane, Oxford, OX3 0BP, UK.  Participants will be given full details of the study protocol and the opportunity to ask 
questions.  All participants will give written informed consent prior to participation. 
Participants 
A sample size of 40 participants will be recruited to allow for any dropouts during the study. Healthy male and female 
adult participants (aged 18-60 years) will be recruited for the study in order to determine if ME can have an affect on 
subjects without impaired glucose tolerance.   
Exclusion Criteria   
The exclusion criteria of the MULBERRY trial are listed in table 1.  
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In addition, participants will be excluded if they are unable to comply with experimental procedures or do not follow GR 
and IR testing safety guidelines.  
Suspension Criteria 
All adverse events will be monitored and recorded from the time of the screening visit through 24 hours after treatment 
visit. Subjects may be excluded or have the study product discontinued if the investigator decides discontinuation of the 
study product is in the best medical interest of the subject (e.g., due to noncompliance, changes in medications or dietary 
supplements, an adverse event or serious adverse event, or a change in medical status) or if the subject requests 
withdrawal from the study. 
Sample Size 
A recent study in India (which is yet to be published) in 12 healthy individuals age 18-25 using 250mg ME dose showed a 
reduction in the glycaemic index of maltodextrin by 58% when compared to placebo. A sample size of 30 would allow 
over 90% power to detect a difference of a similar size.  Being more conservative and allowing for a smaller difference to 
be detected in the lower concentration doses, 30 participants would still allow at least 80% power to detect a difference of 
25% in the incremental Area Under the Curve (iAUC).  In order to account for a potential loss to follow up, and the 
possibility that our sample size may be inaccurate as it is based on a small pilot sample we will therefore recruit 40 
participants.  
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Randomisation 
Researchers recruiting the participants will be unaware of the allocation sequence (concealed allocation).  Assignment of 
participants to a participant number will be done according to their chronological order of enrolment in the study.  The 
allocated participant number will identify the participants and their corresponding intervention sequence. A code break for 
the randomisation will be kept by the Principal Investigator and will only be broken in terms of a serious adverse event. 
Blinding (Treatment / Placebo) 
Four products will be tested in this study - one placebo reference product (four capsules containing 125mg 
microcrystalline cellulose) and three test products containing different doses of mulberry extract (test product groups 
receive either 1, 2, or 4 capsules containing 125mg ME, with either 3, 2, or 0 placebo capsules respectively so that 
participants always take 4 capsules). The study products are double blinded to both investigator and subject. Each 
test/reference product will be co-administered with 50g maltodextrin dissolved in 250ml water. Products will be produced 
by Phynova and delivered to the study centre labelled as ‘Product variant A’, ‘Product variant B’, ‘Product variant C’ and 
‘Product variant D’ with sealed envelopes labelled with participant number and the intervention sequence for the 
respective participant.  
Study Period 
In each participant, the reference product and test products will be tested in random order on (four) separate days, with at 
least a two-day gap between measurements to minimise carry over effects.  The study schedule is summarised in Table 2.  
Outcomes 
Primary outcome:  
iAUC for plasma glucose concentration over 120 minutes. 
Secondary outcomes: 
• iAUC for plasma insulin concentration over 120 minutes. 
• Gastrointestinal tolerability – abdominal bloating may be experienced due to reduced carbohydrate absorption. 
Gastrointestinal symptoms will be measured via questionnaire for 24 hours following each study visit. Subjects will 
use a 5-point scale to rate stool consistency for each bowel movement for 0-24 h after the study product consumption. 
The five-point scale includes: 1=watery, 2=loose/mushy, 3=soft, 4=formed, 5=hard. Frequency and intensity will be 
set to a 10-centimeter (cm) line scale (0 representing “Absent” for frequency and “Usual” for intensity; 10 
representing “More than usual” for frequency and “Severe” for intensity). 
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Recruitment 
Participants	  will	  be	  recruited	  following	  local	  advertisements	  and	  all	  participants will be given full details of the study 
protocol and the opportunity to ask questions.  All participants will give written informed consent prior to participation 
and	  will	  be	  paid	  £10	  per	  visit,	  on	  completion	  of	  all	  four	  visits.	  This	  has	  been	  determined	  as	  an	  appropriate	  amount	  to	  cover	  and	  travel	  costs	  and	  the	  time	  spent	  during	  each	  visit.	  	  
Procedures / Study Schedule 
The study will be conducted by Good Clinical Practice (GCP) certified researchers. The reference product and test 
products will be administered to participants in a randomised, repeated measures design.  On the day prior to a test, 
participants will be asked to restrict their intake of alcohol and caffeine-containing drinks and to restrict their participation 
in intense physical activity (for example, long periods at the gym, excessive swimming, running, aerobics). Participants 
will also be told not to eat or drink after 10.00 pm the night before a test, although water will be allowed in moderation. 
Participants will be studied in the morning after an overnight fast.  Participants will consume the products at a comfortable 
pace, within 5 minutes.  The reference product and test products will be served with 50g maltodextrin dissolved in 250 ml 
water.  Participants will remain sedentary during each test session and will not consume any additional food or fluid. 
Participants will be instructed to record stool consistency for the first bowel movement after their visit and the frequency 
and intensity of gastro intestinal symptoms for 0-24 hours after the study product consumption. 
All anthropometric measures will be taken, using standard methods, in the morning, after an overnight fast.  
 Height and weight  
 BMI will be calculated using the standard formula: weight (kg) / height (m2)  
 Waist and hip circumference 
The glycaemic response method used is adapted from that described by Brouns et al.  [22] and is carried out in accordance 
with the ISO 26642:2010 standards. Blood measurements will be taken at -5 min and 0 min before consumption of the 
reference product/test products and the baseline value taken as a mean of these two values.  Further blood measurements 
will be taken at 15, 30, 45, 60, 90 and 120 minutes after starting to eat.  Blood glucose will be measured using the 
HemoCue Glucose 201+ analyser (HemoCue® Ltd).  The same time points will be used for determining insulin levels. At 
each test time point, 300 µL of capillary blood (from finger pricks) will be obtained. Finger pricks will be made using the 
Unistik 3 single-use lancing device (Owen Mumford, Woodstock, UK) and blood will be collected into chilled 
Microvette® capillary blood collection tubes treated with di Potassium EDTA (CB 300 K2E; Sarstedt Ltd., Leicester, 
UK).  The Microvette® tubes will then be centrifuged and 200 µL of the supernatant plasma obtained. Insulin 
concentrations in the plasma samples will be determined by electrochemiluminescence immunoassay using an automated 
analyzer (Cobas® E411; Roche diagnostics, Burgess Hill, UK).  The Cobas® system is a reliable method of plasma 
insulin determination.  The unit of measurement is µU/ml. Sufficient blood is taken to enable 2 sets of analysis to be 
performed at every time point thus greatly reducing the likelihood of missing data.  
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Statistical Analysis 
This is the first rigorous study of IM and should therefore be considered as a pilot study from a statistical perspective. We 
will calculate the incremental area under the curve for all 4 study products and compare using repeated measures ANOVA 
to determine whether there is a statistically significant difference in plasma glucose levels and in secondary outcome 
measure over the 120 minute period.  All models will control for the possible confounding effects of sex and BMI.   The 
presence/absence of gastrointestinal symptoms in the 24 hours following the study visit will be assessed using logistic 
regression models.  We anticipate a low likelihood of missing data (as sufficient blood is taken for a second analysis to be 
performed if the first analysis fails) and our glucose values will be measured in real time. We anticipate monophasic or 
biphasic glucose and insulin curve responses and will use a 2nd order interpolation method for missing data, provided that 
no other data is missing from the two neighbouring time points at either side of a missing data set and that the baseline 
and end data values are obtained. If the baseline or end points are missing or more than one data point within five 
neighbouring time points, this data set will be deemed unsuitable and not be included in the analysis.   
Discussion 
In this paper, we have suggested the clinical trial design of a dietary supplement to reduce glucose excursions without a 
disproportionate increase in insulin release. This pilot study will influence further work on a larger scale RCT. In this 
study we aim to confirm the standard dose of IminoNorm that can be consumed with food. In addition, we aim to 
determine the magnitude of clinical effect and to measure the frequency and intensity of any gastrointestinal side effects. 
Based on the results, we will aim to design a larger RCT to investigate the protective effect of ME on the development of 
pre-diabetes and diabetes in at risk individuals or the population as a whole. The treatment effect size may be used to 
determine the sample size of a larger study based on similar studies on the prevention of T2DM As mentioned previously, 
ME may also have a positive effect on lipid profiles and we may decide to include further endpoints in future larger trials. 
Glucose-lowering agents show ethnic variations and future work should include assessment in more ethnically diverse 
populations.  
Trial Status 
We have now finished recruiting and most of the participants have completed all 4 visits.  
List of Abbreviations 
ME: Mulberry Extract, T2DM: Type 2 Diabetes Mellitus, BMI: Body Mass Index, TCM: Tradition Chinese Medicine, 
DNJ: 1-deoxynojirimycin, GR: Glycaemic Response, IR: Insulinaemic Response, UREC: University Research Ethics 
Committee, iAUC: Integral Area Under the Curve, GCP: Good Clinical Practice, ANOVA: Analysis of Variance, RCT: 
Randomised Controlled Trial.  
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Table	  1	  Exclusion	  criteria	  of	  the	  Mulberry	  trial	  
Exclusion	  Criteria	  
1. Aged	  <	  18	  or	  >	  60	  years	  	  
2. Pregnant	  or	  lactating	  	  
3. Body	  mass	  index	  (BMI)	  <	  20kg/m2	  and	  >	  30kg/m2	  	  
4. Fasting	  blood	  glucose	  value	  >	  6.1	  mmol/l	  	  
5. Any	  known	  food	  allergy	  or	  intolerance	  including	  mulberry	  extract	  
6. Medical	  condition(s)	  or	  medication(s)	  known	  to	  affect	  glucose	  regulation	  or	  appetite	  and/or	  influence	  digestion	  
and	  absorption	  of	  nutrients	  	  
7. Known	  history	  of	  diabetes	  mellitus	  (Type	  I/II)	  	  or	  the	  use	  of	  antihyperglycaemic	  drugs	  or	  insulin	  to	  treat	  diabetes	  
and	  related	  conditions	  
8. Use	  steroids,	  protease	  inhibitors	  or	  antipsychotics	  (all	  of	  which	  have	  major	  effects	  on	  glucose	  metabolism	  and	  
body	  fat	  distribution)	  
9. Current	  oral	  hypoglycaemic	  use	  
10. Symptomatic	  IBS	  
11. History	  of	  renal	  or	  liver	  diseases	  
12. History	  of	  clotting	  or	  bleeding	  disorders	  
13. Taken	  antibiotics	  in	  last	  3	  weeks	  prior	  to	  screening	  
14. Taking	  daily	  medications	  or	  dietary	  supplements	  that	  are	  not	  suitable	  for	  the	  study	  in	  the	  opinion	  of	  the	  PI	  
15. Anaemia	  
16. Subject	  to	  a	  major	  medical	  or	  surgical	  event	  requiring	  hospitalization	  within	  the	  preceding	  3	  months	  	  
17. Current	  participation	  in	  another	  clinical	  study.	  
 
	  
Table	  2	  Summary	  of	  MULBERRY	  trial	  schedule 
 Screening	  Visit	   Visit	  1	   Visit	  2	   Visit	  3	   Visit	  4	  
Informed	  Consent	   	   	   	   	   	  
Demographic	  Info	  (age,	  contact	  details	  etc)	   	   	   	   	   	  
Medical	  History	   	   	   	   	   	  
Inclusion/Exclusion	  Criteria	   	   	   	   	   	  
Compliance	  Check	  (fasting,	  drugs	  etc)	   	   	   	   	   	  
Physical	  Exam	  (BMI,	  waist	  circ.	  etc)	   	   	   	   	   	  
Consume	  product	  /	  placebo	  +	  drink	   	   	   	   	   	  
Finger-­‐prick	  glucose	  &	  insulin	  testing	   	   	   	   	   	  
GI	  Questionnaire	  	   	   	   	   	   	  
Adverse	  Event	  Monitoring	   	   	   	   	   	  
 
